Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
FDA-registered manufacturers (Hospira, Fresenius Kabi) operate under cGMP with FDA inspection authority
However, patients with kidney disease require closer monitoring for dehydration and gastrointestinal side effects
Findings: WEIGHT LOSS IN ADOLESCENTS The STEP TEENS study detailed below evaluated the effects of Wegovy on weight loss in obese adolescents aged 12 - 17 years RCT STEP TEENS Study - Wegovy vs Placebo for Weight Loss in Obese Adolescents, NEJM (2022) [PubMed abstract] The STEP TEENS study enrolled 201 obese adolescents aged 12 - 17 years Main inclusion criteria Age 12 to 10% Baseline characteristics Average age 15.4 years Female sex - 62% Average weight - 238 lbs (108 kg) Average BMI - 37 Randomized treatment groups Group 1 (134 patients): Wegovy 2.4 mg once weekly Group 2 (67 patients): Placebo Before treatment, all patients underwent a 12-week run-in phase where they received lifestyle interventions Wegovy was started at 0.25 mg once weekly and titrated to 2.4 mg over 16 weeks Percentage change in BMI from baseline to week 68 Primary outcome: Results Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone Findings: Summary Wegovy caused impressive weight loss in the STEP TEENS study, and its effects were greater than other drugs approved for adolescent obesity (see Qsymia and Saxenda)
Dr Anantharaman R, Senior Endocrinologist at the Magna Centres for Obesity, Diabetes and endocrinology, demanded that the relevant information must be made public
Both are engineered modifications of the native sequence designed to overcome specific limitations of standard IGF-1 particularly its rapid sequestration by insulin-like growth factor binding proteins (IGFBPs)
US$ 22.97
US$ 26.67
US$ 27.34
